Wanbury has received an approval for restructuring of business by way of transferring the Formulation businesses to a subsidiary of the company. The board at its meeting held on February 07, 2013 has approved for the same.
The restructuring is however subject to the approval of the bankers of the company and other regulatory authorities.
Wanbury’s major thrust area lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.
